“In an FDA approved study, 78% of patients with mild cognitive impairment or early Alzheimer’s improved over their personal baseline after six months of this non-invasive treatment,” said Cerezen’s Chief Medical Advisor, Jack Juni, M.D.
Latest press releases related to Alzheimer’s treatment and Cerezen™
“In an FDA approved study, 78% of patients with mild cognitive impairment or early Alzheimer’s improved over their personal baseline after six months of this non-invasive treatment,” said Cerezen’s Chief Medical Advisor, Jack Juni, M.D.
Cerezen™, a new treatment which has been shown to reverse symptoms of Alzheimer’s in some cases, was certified in the EU this month.
